Journal: Thoracic Cancer

Article Title: Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1 , IDO , TIM ‐3, FOXP3 + and CD8 expressions in patients with advanced esophageal squamous cell carcinoma

doi: 10.1111/1759-7714.14683

Figure Lengend Snippet: CD8 expression in different groups and tissues and the correlation of CD8 expression with N stage. (a) Representative images of CD8 (brown) and nucleus (blue) staining in one patient. CD8+ expression in control group tumor tissue (C‐tumor), control group paratumor tissue (C‐paratumor) and in the treatment group tumor tissue (T‐tumor), and paratumor tissue (T‐paratumor). (b) Decreased CD8 expression in patients treated preoperatively with chemoimmunotherapy (CI) as compared with patients treated preoperatively without CI in tumor ( p < 0.0001) and paratumor tissues ( p = 0.0094). Each dot represents one slide. (c) Correlation analysis between the cell densities for CD8 and N stage was performed using linear regression and correlation coefficient. CD8 IOD, CD8 integrated optical density; N stage, lymph node stage.

Article Snippet: Whole section slides of FFPE tumor and paratumor were stained using a Dako instrument with PD‐L1 (bs‐1103R, Bioss, 1:200 dilution), IDO (13268‐1‐AP, Proteintech, 1:200 dilution), CD8(bs‐10699R, Bioss, 1:200 dilution), TIM‐3 (bs‐10699R, Bioss, 1:200 dilution) and FOXP3+ (bs‐10699R, Bioss, 1:200 dilution) antibodies.

Techniques: Expressing, Staining

Journal: Thoracic Cancer

Article Title: Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1 , IDO , TIM ‐3, FOXP3 + and CD8 expressions in patients with advanced esophageal squamous cell carcinoma

doi: 10.1111/1759-7714.14683

Figure Lengend Snippet: The correlation of PD‐L1, FOXP3+, IDO, TIM‐3, CD8 expression in nontreated esophageal squamous cell carcinoma (ESCC) patients. (a) Correlation between the integrated optical densities of PD‐L1 and FOXP3+ (a, Spearman's R = −0.4483, p = 0.019), IDO (b, Spearman's R = −0.4371, p = 0.0236) in nontreated ESCC paratumor tissues of patients. (b) Correlation analysis between the integrated optical densities for PD‐L1 and FOXP3+ was performed using linear regression and correlation coefficient (Spearman's R = 0.5263, p = 0.0048), in nontreated ESCC paratumor tissues of patients.

Article Snippet: Whole section slides of FFPE tumor and paratumor were stained using a Dako instrument with PD‐L1 (bs‐1103R, Bioss, 1:200 dilution), IDO (13268‐1‐AP, Proteintech, 1:200 dilution), CD8(bs‐10699R, Bioss, 1:200 dilution), TIM‐3 (bs‐10699R, Bioss, 1:200 dilution) and FOXP3+ (bs‐10699R, Bioss, 1:200 dilution) antibodies.

Techniques: Expressing

Journal: Thoracic Cancer

Article Title: Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1 , IDO , TIM ‐3, FOXP3 + and CD8 expressions in patients with advanced esophageal squamous cell carcinoma

doi: 10.1111/1759-7714.14683

Figure Lengend Snippet: Correlation among CD8, IDO and TIM‐3, FOXP3+ expression in treatment group tumor tissue. (a) A high positive correlation was observed between CD8 and IDO expression (Spearman's R = 0.8454, p = 2.8514e‐8). (b) A moderate positive correlation was observed between IDO and FOXP3+ expression (Spearman's R = 0.4217, p = 0.0285). (c) A high negative correlation was observed between TIM‐3 and IDO expression (Spearman's R = −0.5854, p = 0.0013). (d) A high negative correlation was observed between TIM‐3 and CD8 (Spearman's R = −0.744, p = 0.00000864) .

Article Snippet: Whole section slides of FFPE tumor and paratumor were stained using a Dako instrument with PD‐L1 (bs‐1103R, Bioss, 1:200 dilution), IDO (13268‐1‐AP, Proteintech, 1:200 dilution), CD8(bs‐10699R, Bioss, 1:200 dilution), TIM‐3 (bs‐10699R, Bioss, 1:200 dilution) and FOXP3+ (bs‐10699R, Bioss, 1:200 dilution) antibodies.

Techniques: Expressing

Journal: Thoracic Cancer

Article Title: Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1 , IDO , TIM ‐3, FOXP3 + and CD8 expressions in patients with advanced esophageal squamous cell carcinoma

doi: 10.1111/1759-7714.14683

Figure Lengend Snippet: Correlation among CD8, IDO and TIM‐3, FOXP3+ expression in treatment paratumor tissue. (a) A moderate positive correlation was observed between IDO and CD8 (Spearman's R = 0.5153, p = 0.0059). (b) A moderate positive correlation was observed between IDO and FOXP3+ expression (Spearman's R = 0.4217, p = 0.0285). (c) A moderate positive correlation was observed between IDO and TIM‐3 expression (Spearman's R = 0.4303, p = 0.0251). (d) A high positive correlation was observed between TIM‐3 and CD8 expression (Spearman's R = 0.5925, p = 0.0011). (e) A high positive correlation was observed between TIM‐3 and FOXP3+ expression (Spearman's R = 0.635, p = 0.0002)

Article Snippet: Whole section slides of FFPE tumor and paratumor were stained using a Dako instrument with PD‐L1 (bs‐1103R, Bioss, 1:200 dilution), IDO (13268‐1‐AP, Proteintech, 1:200 dilution), CD8(bs‐10699R, Bioss, 1:200 dilution), TIM‐3 (bs‐10699R, Bioss, 1:200 dilution) and FOXP3+ (bs‐10699R, Bioss, 1:200 dilution) antibodies.

Techniques: Expressing

Journal: Nature Communications

Article Title: Th1-poised naive CD4 T cell subpopulation reflects anti-tumor immunity and autoimmune disease

doi: 10.1038/s41467-025-57237-3

Figure Lengend Snippet: a Representative histogram of IL-7R, Adgre5, CD5 expression in IL-18R/Ly6C double-positive (DP) and double-negative (DN) naive CD4 T cells. b Representative dot plot of IL-18R and Ly6C expression in IL-7R sup-hi and IL-7R low naive CD4 T cells and memory-phenotype CD4 T cells (MP). c Representative dot plot of IL-18R/Ly6C DP population in naive CD4 T cells from each indicated tissue. d Tissue distribution of IL-18R/Ly6C DP population in naive CD4 T cells ( n = 10). e Representative histogram of naive CD4 T cells from spleen and thymus. f UMAP of murine naïve CD4 T cells from two different tissues (thymic CD4 SP and spleen). Cells were colored by cluster identity using label transfer of naïve CD4 T cell clusters from Fig. . g Stacked bar graph showing the proportion of naïve CD4 T cell clusters from thymus (Thy) and spleen (Spl). h Dot plots showing the distribution of pseudotime for the single cells in each cluster. i Alluvial plot to track the clonal population in thymus (Thy) and spleen (Spl) using TCR-seq data. j Box plots for the Shannon diversity index of TCR repertoire for each cluster in each tissue. k Expression of Ly6C and IL-18R in naive CD4 and CD8 single-positive (SP) cells in thymocytes stimulated with anti-CD3 for 3 days. l Proportion of Ly6C + cells in SP CD4 naive thymocytes stimulated by the indicated cytokines for 3 days ( n = 5). Statistical significance was confirmed by two-sided Mann-Whitney U -test with control group and each experimental group ( p = 0.0079). m Proportion of Ly6C + naive CD4 T cells in the splenocyte of WT, Stat1 -/- , Ifnar -/- , and Ifnar -/- Ifngr -/- mice (WT n = 5, Stat1 KO n = 5, Ifnar1 KO n = 3, Ifnar1 Ifngr1 KO n = 2). Data presented as the mean ± S.D. Statistical significance was confirmed by the two-sided Mann-Whitney U -test (* p < 0.05, ** p < 0.01, *** p < 0.001). Source data and exact statistics value are provided as a Source Data file.

Article Snippet: CD8 and NK depletion was performed by a single i.p injection of 200μg of anti-CD8 antibody (clone 2.43, BioXcell, #BE0061, lot 811521N1) and anti-NK1.1 antibody (clone PK136, BioXcell, #BE0036 lot 828622A2).

Techniques: Expressing, MANN-WHITNEY, Control

Journal: Nature Communications

Article Title: Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

doi: 10.1038/s41467-021-26830-7

Figure Lengend Snippet: a – e 1-week-old normal dogs were either co-injected with AAV.CK8.SpCas9 and AAV.RSV.AP or injected with AAV.RSV.AP only. a Representative HE, AP, CD4, and CD8 stainings. b Cas9 , and AP vector genome quantification (N, n = 5; others, n = 3). c Serum Cas9 antibody (Naive, n = 8; 6wks., n = 1). d Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 3). e Muscle cytokine transcript quantification (Naive, n = 8; others, n = 3). f - j Similar to a - e except 1-m-old dogs were injected. f Representative HE, AP, CD4, and CD8 stainings. Arrowhead, T-cell infiltration wiped out AP expression. g Cas9 and AP vector genome quantification ( N , n = 4; others, n = 3). h Serum Cas9 antibody ( N , n = 12; 6wks., n = 1). i Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 1). j Muscle cytokine transcript quantification ( N , n = 14; others, n = 3). k – p Similar to a - e except adult dogs were injected with either AAV.CK8.SpCas9 or AAV.RSV.AP. k Representative HE, AP, CD8, and granzyme B stainings. The boxed region was magnified. Yellow arrowhead, a dying myofiber lost dystrophin expression and infiltrated with CD8 + and granzyme B + T cells. l CD8 + T-cell quantification ( n = 3 for all categories). m Dystrophin and Cas9 western blot. n Serum Cas9 antibody (Naive, n = 27; others, n = 3). o Cas9 ELISpot assay on lymphocytes (Naive, n = 6; others, n = 3). p Muscle cytokine transcript quantification from adult dogs ( N , n = 12; others, n = 3). Immune cells are stained in dark brown, and AP is stained in blue. AP, alkaline phosphatase. N, No AAV. N/A, non-applicable. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for c , h , i , One-way ANOVA with Tukey’s multiple comparisons for b , e , g , j , l , and n - p and Student’s t-test for d . See source data file for the exact p -value. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Rat monoclonal IgG1 antibody against canine CD8 (Catalog# MCA1039, clone YCATE 55.9, Lot # 149349, 1:200, Bio-Rad Laboratories, Inc.) was used to detect CD8 + T and was visualized using a biotin-conjugated goat anti-rat IgG (H + L) antibody (A10517, Lot # 1441195, 1:1000, ThermoFisher Scientific).

Techniques: Injection, Plasmid Preparation, Enzyme-linked Immunospot, Expressing, Western Blot, Staining

Journal: Nature Communications

Article Title: Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

doi: 10.1038/s41467-021-26830-7

Figure Lengend Snippet: a Representative HE, dystrophin, CD4, and CD8 stainings from biopsy. b , Representative dystrophin and CD8 stainings from necropsied muscles. c Representative HE, dystrophin, CD8, and granzyme B staining from a necropsied muscle. d Cas9 and gRNA vector genome quantification (N, n = 7; 3wks., n = 1; 6wks., n = 11). e Cas9 transcript quantification ( N , n = 7; 3wks., n = 1; 6wks., n = 11). f Serum Cas9 antibody ( N , n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 10 weeks after birth, respectively; dog#1, n = 1 for 0, 4–10 weeks after birth). g PBMC IFN-γ ELISPOT against Cas9 ( N , n = 11; dog #1 n = 1 for all-time points). h Representative HE, dystrophin, CD4, and CD8 staining from biopsy. i Representative dystrophin and CD8 staining from necropsied muscles. j Representative HE, dystrophin, CD8, and granzyme B stainings from a necropsied muscle. k Cas9 and gRNA vector genome quantification ( N , n = 7; 3wks., n = 1; 6wks., n = 18). l Cas9 transcript quantification ( N , n = 7, 3wks., n = 1; 6wks., n = 18). m Serum Cas9 antibody ( N , n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for 0, 4–16 weeks after birth). n Cas9 specific IFN-γ ELISpot assay on PBMCs ( N , n = 11; dog #1 n = 1 for all-time points). o Representative HE, dystrophin, CD4 and CD8 staining from the control dog that received the micro-dystrophin vector. p Muscle cytokine transcript quantification from all three dogs ( N , n = 7;dog#1, 3wks. n = 1, 6wks. n = 11; dog#2, 3wks. n = 1, 12wks. n = 18; μDys injected dog, 6wks. n = 1, 24wks. n = 1). Immune cells are stained in dark brown. Arrow, a granzyme B-positive T cell. N , No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford–Howell test for d – g and k – n , One-way ANOVA with Tukey’s multiple comparisons for p . See source data file for the exact p -value. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Rat monoclonal IgG1 antibody against canine CD8 (Catalog# MCA1039, clone YCATE 55.9, Lot # 149349, 1:200, Bio-Rad Laboratories, Inc.) was used to detect CD8 + T and was visualized using a biotin-conjugated goat anti-rat IgG (H + L) antibody (A10517, Lot # 1441195, 1:1000, ThermoFisher Scientific).

Techniques: Muscles, Staining, Plasmid Preparation, Enzyme-linked Immunospot, Control, Injection

Journal: Nature Communications

Article Title: Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

doi: 10.1038/s41467-021-26830-7

Figure Lengend Snippet: a Representative HE, AP CD4, and CD8 stainings. b Cas9 and AP vector genome quantification ( N , n = 7; others, n = 1). c Cas9 and AP transcript quantification ( N , n = 7; others, n = 1). d AP + myofiber quantification ( n = 1 in all categories). e Serum Cas9 antibody ( N , n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#1, n = 1 for all-time points). f Cas9-specific IFN-γ ELISpot assay on PBMCs ( N , n = 11; dog #1 n = 1 for all-time points). g Representative HE, AP, CD4, and CD8 staining. h Cas9 and AP vector genome quantification ( N , n = 7; others, n = 1). i Cas9 and AP transcript quantification (in both panels: N , n = 7; each other group, n = 1). j AP + myofiber quantification ( n = 1 in each group). k Serum Cas9 antibody ( N , n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for all time points). l , PBMC IFN-γ ELISpot against Cas9 ( N , n = 11; dog #1 n = 1 for all time points). m Representative HE, AP, CD4, and CD8 stainings. n AP vector genome quantification ( N , n = 7; others, n = 1). o AP transcript quantification ( N , n = 7; others, n = 1). p Muscle cytokine transcript quantification from all 3 dogs at the indicated time points post-injection ( N , n = 14; dog#1, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog#2, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog injected with AP vector only, 6wks. n = 1, 52 wks. n = 1). AP, alkaline phosphatase. N, No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for b , c , e , f , h , i , k , l , n , o , and One-way ANOVA with Tukey’s multiple comparisons for p . See source data file for exact p -value. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Rat monoclonal IgG1 antibody against canine CD8 (Catalog# MCA1039, clone YCATE 55.9, Lot # 149349, 1:200, Bio-Rad Laboratories, Inc.) was used to detect CD8 + T and was visualized using a biotin-conjugated goat anti-rat IgG (H + L) antibody (A10517, Lot # 1441195, 1:1000, ThermoFisher Scientific).

Techniques: Plasmid Preparation, Enzyme-linked Immunospot, Staining, Injection

Journal: International Journal of Molecular Sciences

Article Title: HLA Class I Expression Is Associated with DNA Damage and Immune Cell Infiltration into Dysplastic and Neoplastic Lesions in Ulcerative Colitis

doi: 10.3390/ijms241713648

Figure Lengend Snippet: Immunohistochemical staining of CD8, CD68, CD163, and FOXP3 in tissues from SCRC, UC, and dysplasia/CC with low and high HLA-I. Representative immunohistochemical images of immune cell markers such as CD8 (cytotoxic T cell marker), CD68 (M1-like macrophage marker), CD163 (M2-like macrophage marker), and FOXP3 (regulatory T cell marker) in tissues from SCRC, UC, and dysplasia/CC with low and high HLA-I. Scale bar, 25 μm. (original magnification, ×40). SCRC, sporadic colorectal cancer; UC, ulcerative colitis; CC, colitis cancer.

Article Snippet: Nonspecific binding sites were blocked by incubation with Protein Block Serum-Free Reagent for 30 min, and the sections were incubated overnight at 4 °C with the primary antibodies against HLA Class I-A, B, C (Hokudo, Sapporo, Japan, EMR8-5, mouse mAb, 1:400 dilution) and CD8 (Abcam, Cambridge, MA, USA, ab4055, rabbit pAb, 1:400 dilution).

Techniques: Immunohistochemistry, Staining, Marker

Journal: International Journal of Molecular Sciences

Article Title: HLA Class I Expression Is Associated with DNA Damage and Immune Cell Infiltration into Dysplastic and Neoplastic Lesions in Ulcerative Colitis

doi: 10.3390/ijms241713648

Figure Lengend Snippet: Comparison of infiltrating immune cell counts between SCRC, UC, and dysplasia/CC with low and high HLA-I. ( A ) The infiltrating cell number of CD8 (cytotoxic T cell marker) positive cells in SCRC, UC, and dysplasia/CC with low and high HLA-I. ( B ) The infiltrating cell number of FOXP3 (regulatory T cell marker) positive cells in SCRC, UC, and dysplasia/CC with low and high HLA-I. ( C ) The infiltrating cell number of CD68 (M1-like pro-inflammatory macrophage marker) positive cells in SCRC, UC, and dysplasia/CC with low and high HLA-I. ( D ) The infiltrating cell number of CD163 (M2-like anti-inflammatory macrophage marker) positive cells in SCRC, UC, and dysplasia/CC with low and high HLA-I. * p < 0.05; ** p < 0.01. SCRC, sporadic colorectal cancer; UC, ulcerative colitis; CC, colitis.

Article Snippet: Nonspecific binding sites were blocked by incubation with Protein Block Serum-Free Reagent for 30 min, and the sections were incubated overnight at 4 °C with the primary antibodies against HLA Class I-A, B, C (Hokudo, Sapporo, Japan, EMR8-5, mouse mAb, 1:400 dilution) and CD8 (Abcam, Cambridge, MA, USA, ab4055, rabbit pAb, 1:400 dilution).

Techniques: Comparison, Marker

Journal: International Journal of Molecular Sciences

Article Title: HLA Class I Expression Is Associated with DNA Damage and Immune Cell Infiltration into Dysplastic and Neoplastic Lesions in Ulcerative Colitis

doi: 10.3390/ijms241713648

Figure Lengend Snippet: Immunofluorescence analysis for HLA-I and CD8 expression in dysplasia/CC tissues. Representative dysplasia/CC tissues with low ( A ) or high ( B ) HLA-I expression were immunostained with anti-HLA-I (green) and anti-CD8 (red) antibodies. All sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar = 25 μm (original magnification, ×40).

Article Snippet: Nonspecific binding sites were blocked by incubation with Protein Block Serum-Free Reagent for 30 min, and the sections were incubated overnight at 4 °C with the primary antibodies against HLA Class I-A, B, C (Hokudo, Sapporo, Japan, EMR8-5, mouse mAb, 1:400 dilution) and CD8 (Abcam, Cambridge, MA, USA, ab4055, rabbit pAb, 1:400 dilution).

Techniques: Immunofluorescence, Expressing

Journal:

Article Title: ? 2 -Glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice

doi: 10.1046/j.1365-2249.1998.00476.x

Figure Lengend Snippet: Immunoperoxidase staining of cryostat pancreas sections of a 20-week-old NOD female mouse using different MoAbs defining CD4+ T lymphocytes (A), CD8+ T lymphocytes (B), sIg+ B lymphocytes (C).

Article Snippet: Immunohistochemical study For the immunohistochemical study, the following antibodies were used: rat anti-mouse L3T4 (CD4) (clone GK1·5, lot no. J0419) which reacts with helper/inducer T lymphocytes, and rat anti-mouse Lyt-2 (CD8) (clone 53-6·7, lot no. F0115) which mainly reacts with suppressor/cytotoxic T lymphocytes, purchased from Becton Dickinson (Mountain View, CA), goat anti-mouse immunoglobulins (IgA + IgG + IgM) (lot no. 30162), purchased from Organon Teknika N.V.-Cappel Products (West Chester, PA), rabbit anti-mouse IgG1 (lot no. 90102332), IgG2a (lot no. 80801705), IgG2b (lot no. 7110218), IgG3 (lot no. 80801704), biotinylated goat anti-rat IgG, biotinylated goat anti-rabbit IgG purchased from Zymed Labs. To stain specific antigens, 5 μm thick cryostat sections of pancreas from 20-week-old female non-diabetic NOD mice were dried in room air for 15 min, fixed in acetone for 30 min and then again air-dried for 30 min. After a 10-min incubation with 10% normal serum, an appropriately diluted antibody for the specific antigen was overlaid for 60 min, then the preparations were washed three times in PBS and incubated with biotinylated anti-IgG for 30 min.

Techniques: Immunoperoxidase Staining

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Concentrations of primary antibodies.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques: Concentration Assay

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: (A) HE(x200). (B) Immunohistochemical (IHC, x400) CD8+, CD4+, FOXP3+Tregs, and PD-L1 of Tonsil (positive tissue) and breast tumor. (C) Immunofluorescence (IF, x20) Blue: DAPI; Red: CD105; Green: NG2 (The short arrow shows microvessels not covered by pericyte cells, the long arrow shows microvessels covered by pericyte cells).

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques: Immunohistochemical staining, Immunofluorescence

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Changes of sTILs, PD-L1, MVD, and MPI in non-pCR group and pCR group after NAC.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Univariate and multivariate analysis of pCR after NAC.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Relationship between the baseline ratios of populations and pCR.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: The relationship between the changes of sTILs, PD-L1, MVD, MPI, and DFS before and after NAC. (A) Survival analysis between pCR group and Non-pCR group. (B) Survival analysis of sTILs change. (C) Survival analysis of CD8+T change. (D) Survival analysis of CD4+T change. (E) Survival analysis of FOXP3+ Tregs change. (F) Survival analysis of PD-L1 change. (G) Survival analysis of MVD change. (H) Survival analysis of MPI change.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: The relationship between DFS and sTILs, PD-L1, MVD, and MPI in Metastatic lymph node (LN). (A) Survival analysis of LN sTILs. (B) Survival analysis of LN CD8+ T cells. (C) Survival analysis of LN CD4+ T cells. (D) Survival analysis of LN FOXP3+ Tregs. (E) Survival analysis of LN PD-L1. (F) Survival analysis of LN MVD. (G) Survival analysis of LN MPI.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques: